Hospital-related characteristics of the studied population.
No PTE | PTE | ||
---|---|---|---|
Prescribed Drugs | N=131 | N=84 | - |
Hydroxychloroquine | 61 (46.6) | 20 (23.8) | 0.001a) |
Antibiotic | 118 (9.1) | 74 (88.1) | 0.647 |
Remdesivir | 23 (17.6) | 14 (16.7) | 0.866 |
Interferon | 18 (13.8) | 4 (4.8) | 0.034a) |
Favipiravir | 2 (1.53) | 1 (1.20) | 0.845 |
Corticosteroid | 87 (66.4) | 68 (81.0) | 0.020a) |
Kaletra | 13 (9.1) | 7 (8.3) | 0.695 |
Unknown | 1 (0.75) | 15 (15.1) | |
Anticoagulation prior to PTE diagnosis, N (%) | N=130 | N=84 | - |
None | 34 (26.2) | 38 (45.2) | 0.004a) |
Prophylactic doses | 71 (54.6) | 27 (32.1) | 0.001a) |
Intermediate doses | 6 (4.6) | 8 (9.5) | 0.156 |
Therapeutic doses | 19 (14.6) | 11 (13.1) | 0.754 |
Unknown | 2 (1.5) | 15 (15.1) | |
Side effects of anticoagulants, N (%) | N=132 | N=84 | - |
GI-bleeding | 6 (4.6) | 6/84 (7.2) | 0.389 |
Hemoptysis | 8 (6.1) | 5/84 (6.0) | 0.0001a) |
Hematuria | 2 (1.5) | 3/84 (3.6) | 0.327 |
Other | 2 (1.5) | 3/84 (3.6) | 0.327 |
Missing | 0 (0) | 15 (15.1) | |
Disease severitya), N (%) | 13 (9.9) | 10 (10.1) | 0.949 |
Hospitalization outcome, N (%) | N=132 | N=99 | - |
Intensive care unit admission | 59 (44.7) | 47 (47.5) | 0.675 |
Non-invasive ventilation | 12 (9.1) | 25 (25.3) | 0.001a) |
Intubation | 18 (13.6) | 19 (19.2) | 0.255 |
Discharge | 124 (93.9) | 81 (81.8) | 0.004a) |
Death | 8 (6.1) | 18 (18.2) | |
Interval times-day, median (IQR) | N=132 | N=99 | - |
Symptom to admission | 7 (4–10) | 7 (4–14) | 0.467 |
Symptom to computed tomography, scan | 13 (7–17) | 14 (6–20) | 0.841 |
Admission to computed tomography, scan | 2 (0–7) | 4 (3–8) | 0.607 |
Admission to intensive care unit | 2 (0–5) | 3 (1–6) | 0.247 |
Admission to discharged | 9 (5–14) | 10 (7–19) | 0.033a) |
Admission to dead | 13 (12–21) | 8 (13.5–30) | 0.837 |
a)Chi2/exact test for categorical variable, independent T-test or Wilcoxon rank-sum test for continuous variable were significant if
Abbreviation: PTE, pulmonary thromboembolism.